Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Darina Zammoeva"'
Autor:
Aleksina Shatilova, Larisa Girshova, Daniil Zaytsev, Irina Budaeva, Yuliya Mirolyubova, Darya Ryzhkova, Roman Grozov, Konstantin Bogdanov, Tatiana Nikulina, Dmitriy Motorin, Darina Zammoeva, Svetlana Efremova, Vladimir Ivanov, Alexey Petukhov, Yuliya Alekseeva, Andrey Zaritskey
Publikováno v:
BMC Women's Health, Vol 21, Iss 1, Pp 1-7 (2021)
Abstract Background Myeloid sarcoma (MS) is a very rare condition, develops both in patients with other hematological neoplasms, and as isolated tumor. MS of the gynecologic tract is extremely rare. An available literature data about diagnosis and ma
Externí odkaz:
https://doaj.org/article/e22e3e6b95754c38a975215774eb3796
Autor:
Elza Lomaia, Tamara Chitanava, Yulia Vlasova, Dmitry Motorin, Sergey Voloshin, Darina Zammoeva, Renat Badaev, Yulia Matvienko, Elizaveta Efremova, Ekaterina Mileeva, Nadia Siordia, Olga Kulemina, Eugenia Sbityakova, Natalia Lazorko, Julia Alexeeva, Irina Martynkevich, Elena Karyagina, Natalia Ilyina, Nadezhda Medvedeva, Natalia Dorofeeva, Tatiana Shneider, Svetlana Stepanova, Vasily Shuvaev, Elena Morozova
Publikováno v:
Blood. 140:12192-12193
Autor:
A.Yu. Zaritskey, R.I. Vabishchevich, Yu.V. Mirolyubova, Konstantin Bogdanov, D.V. Zaitsev, Alexina Shatilova, Darina Zammoeva, Irina Budaeva, R.Sh. Badaev, VV Ivanov, Dmitry Motorin, Alexey Petrov, Larisa Girshova, S.V. Efremova, Elena Tochenaya, TS Nikulina, Yu.A. Alekseeva
Publikováno v:
Clinical oncohematology. 14:299-307
Aim. To assess the efficacy, safety, and tolerance of gemtuzumab ozogamicin (GO) combined with FLAG/FLAG-Ida chemotherapy or azacitidine in patients with relapsed/refractory acute myeloblastic leukemia (AML) in clinical practice. Materials & Methods.
Autor:
S.V. Efremova, A.V. Petukhov, D.V. Zaitsev, VV Ivanov, Yu.A. Alekseeva, Irina Budaeva, Konstantin Bogdanov, Darina Zammoeva, A.Yu. Zaritskey, Aleksina Shatilova, Roman Grozov, Yu.V. Mirolyubova, Larisa Girshova, Darya Ryzhkova, TS Nikulina, Dmitry Motorin
Publikováno v:
Clinical oncohematology. 14:31-44
Myeloid sarcoma, also known as chloroma or granulocytic sarcoma, is a rare disease characterized by the proliferation of immature myeloid cells in extramedullary lesions. Chloroma is more commonly observed in patients with acute myeloid leukemias, ot
Autor:
Tamara Chitanava, Vasily Shuvaev, Iuliia Matvienko, Irina Martynkevich, Sergey Voloshin, Elizaveta Efremova, Ekaterina Mileeva, Mikhail Fominykh, Anna Kersilova, Elena Koryagina, Natalia Ilyina, Natalia Dorofeeva, Nadezhda Medvedeva, Anna Klimovich, Tatiana Shneider, Svetlana Stepanova, Natalia Polezhajkovskaya, Nadiya Siordiya, Eugenia Sbityakova, Natalia Lazorko, Elena Tochenaya, Dmitry Motorin, Nadezhda Shnalieva, Yulia Alekseeva, Darina Zammoeva, Elza Lomaia
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 22:S288
Autor:
D.V. Zaitsev, YuV Mirolyubova, Konstantin Bogdanov, YuA Alekseeva, EN Goryunova, Darina Zammoeva, Larisa Girshova, EG Ovsyannikova, Irina Budaeva, AYu Zaritskey, OS Pisotskaya, TS Nikulina, Dmitry Motorin, O. Kulemina, RSh Badaev, VV Ivanov
Publikováno v:
Clinical oncohematology. 12:289-296
Aim. To assess the efficacy of FLAG/FLAG-Ida regimen and to identify factors that influence remission, duration of disease-free survival (DFS) and overall survival (OS) of patients with relapsed/refractory acute myeloid leukemia (AML). Materials & Me
Autor:
Larisa Girshova, Dmitry Motorin, Natalia Ilina, RSh Badaev, AYu Zaritskey, Darina Zammoeva, DV Babenetskaya, YuA Alekseeva
Publikováno v:
Kliničeskaâ onkogematologiâ, Vol 12, Iss 1, Pp 37-42 (2018)
Background. Haploidentical bone marrow transplantation (BMT) can be a reliable alternative if a fully matched donor is not available. The main challenges after BMT are a relapse of major disease, graft-versus-host disease (GVHD), and infections. Azac
Autor:
Aleksina Shatilova, Larisa Girshova, Daniil Zaytsev, Irina Budaeva, Yuliya Mirolyubova, Darya Ryzhkova, Roman Grozov, Konstantin Bogdanov, Tatiana Nikulina, Dmitriy Motorin, Darina Zammoeva, Svetlana Efremova, Vladimir Ivanov, Alexey Petukhov, Yury Osipov, Yuliya Alekseeva, Andrey Zaritskey
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:S211
Autor:
OS Pisotskaya, Darina Zammoeva, Larisa Girshova, RSh Badaev, Konstantin Bogdanov, SO Kuzin, Dmitry Motorin, VV Ivanov, Irina Budaeva, EG Ovsyannikova, YuV Mirolyubova, TS Nikulina, YuA Alekseeva, AYu Zaritskii
Publikováno v:
Kliničeskaâ onkogematologiâ, Vol 10, Iss 4, Pp 485-493 (2017)
Background. Acute myeloblastic leukemia (AML) with NPM7 mutation amounts to 30 % of all AML and is characterized by good prognosis with the exception of cases with FLT3-/TD mutation. Despite the good prognosis, the likelihood of relapses in patients
Autor:
Tamara Chitanava, Agniia-Polina Poshivay, Andrey Zaritskey, Vasily Shuvaev, Nadezhda Shnalieva, Darina Zammoeva, Mikhail Fominykh, Irina Martynkevich, Natalia Polezhajkovskaya, NT Siordiya, Eugenia Sbityakova, Anna Kersilova, Elena Koryagina, Nadezhda Medvedeva, Elena Tochenaya, Svetlana Stepanova, Natalia Ilyina, Elza Lomaia, Natalia Lazorko, Elizaveta Efremova, Olga Merzlikina, Anna Klimovich, Tatiana Shneider, Natalia Dorofeeva
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 20:S242
Context Tyrosine kinase inhibitors in third-line therapy (TKI-3L) in chronic-phase chronic myelogenous leukemia (CP CML) is effective in a portion of patients. Meanwhile, it is unclear which patients may benefit from TKI-3L. Objective To identify the